MedInCell Stock Drops 2.23% to €26.34 but Maintains a +69% Yearly Gain
The Montpellier-based biotech's stock falls 2.23% to €26.34 at midday in a declining Paris market. The SBF 120 is down 0.44% and the CAC 40 loses 0.49% during the session. However, the stock still holds a gain of over 69% for the year.
A Retreat Bringing the Stock Back to Its 20-Day Moving Average
MedInCell stock erases part of the rebound that began in early May. Over the week, the stock has dropped 6.2%, after reaching €28.14 on May 15. Nonetheless, the price remains above its 20-day moving average (€25.71), with a limited gap of 2.45%.
The resistance at €28.72, identified in previous sessions and already mentioned in a brief published on May 20, has not been breached. The RSI at 58 remains in the neutral zone, with no overbought signal. The MACD, with its histogram slightly in negative territory (-0.03), indicates a waning of the short-term bullish momentum.
The three-month performance stands at +10.3%, and the one-year performance at +69.06%. Thus, the stock maintains a fundamentally positive trajectory, despite recent fluctuations.
Slight Increase in Net Short Positions, at 2.07% of Capital
According to reviewed declarations, three funds together hold a cumulative net short position of 2.07% of MedInCell's capital. This level has risen by 0.11 points over thirty days, from 1.96% a month ago.
This change does not indicate a massive movement of distrust, but it shows that some institutional investors remain positioned against the stock, or are seeking to hedge exposure. This point should be monitored, though not interpreted in isolation, in a context where the biotech has already experienced several phases of volatility since the beginning of the year.
The company's headquarters are located in Jacou, in the Hérault department, and the chairman of the board is Philippe André Guy. The next technical reference to watch remains the €28.72 resistance, which a return of buyers should surpass to reignite the upward trend.
